CURR vs GSK · rev $37.8M vs P/E 13, $103.31B cap
Currenc Group Inc. Ordinary Shares (CURR) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Currenc Group Inc. Ordinary Shares (CURR) is a software - application company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported CURR revenue for 2025-12-31 was $37.8M. Net income was -$18.4M. Revenue was down 18.6% from 2024-12-31 to 2025-12-31. CURR currently screens at market cap $352.6M.
GSK does not have a complete income-statement cache yet.
CURR currently screens at market cap $352.6M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the CURR and GSK stock pages for the full models.
Not investment advice.